

dermatitis, poison ivy, poison oak or sumac, insect bites, soaps, detergents, cosmetics, jewelry; and for external feminine and anal itching. Caldecort Regular Strength Cream (hydrocortisone 0.50% to 1.0% strength) was approved in August 1991 for OTC use.

Cortaid (hydrocortisone 0.25% to 0.50% strength), marketed by Pfizer, was approved for OTC use in December 1979. The product is indicated for the temporary relief of itching associated with minor skin irritations; inflammations; rashes due to eczema, psoriasis, seborrheic dermatitis, poison ivy, poison oak or sumac, insect bites, soaps, detergents, cosmetics, and jewelry; and for external feminine and anal itching. Cortaid Extra Strength (hydrocortisone 0.50% to 1.0% strength) was approved in August 1991 for OTC use.

Lanacort (hydrocortisone 0.5% to 1.0% strength), manufactured by Comb, Inc., was approved for OTC use in December 1979. The product is indicated for the relief of itching associated with minor skin irritations due to eczema, psoriasis, dermatitis, and external feminine itching, plus irritation due to soaps, cosmetics, and jewelry.

Micatin (miconazole nitrate 2% strength, topical), manufactured by Pfizer, was introduced to the OTC market in March 1982. The product is an antifungal agent that contains the active ingredient miconazole nitrate 2%. It is indicated for tinea cruris (jock itch).

TZ-3 (tioconazole), manufactured by Pfizer Consumer, was approved by the FDA for OTC use in February 1983. However, this drug is no longer available on the market and, therefore, no revenues are available.

Lotrimin AF (clotrimazole) was approved for switch to the OTC market in October 1989. Manufactured by Schering-Plough, Lotrimin AF is available OTC in cream 1%, solution 1%, and lotion 1%, and is indicated for the treatment of dermal infections caused by a variety of pathogenic dermatophytes, yeasts, and *Malassezia furfur* (a fungus). The primary action of clotrimazole is against dividing and growing organisms. The product was first available on the market in January 1990 and is indicated for superficial dermatophyte infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). Lotrimin Ultra 1% was approved for OTC switch in December 2001.

Table 5-8**The Global Market Antiaging and Photodamage Drugs by Type
2001-2011**

Year	Manufacturer Revenue (in millions)					Total	Growth Rate
	Keratolytics	Moisturizers	Retinoids	Sun-screens	Other Agents		
2001							
2002							
2003							
2004							
2005							
2006							
2007							
2008							
2009							
2010							
2011							

Years	Compound Annual Growth Rate					Total
	Keratolytics	Moisturizers	Retinoids	Sun-screens	Other Agents	
2001-2006						
2006-2011						
2001-2011						

Source: Kalorama Information